Malar Zone

In short: Malar zone is the topographic zone located around the zygomatic arch (zygomatic arch + malar eminence) and is at the center of midface hollowing, Ogee curve loss and nasolabial fold deepening caused by deep medial cheek fat atrophy. Supraperiosteal bolus injection with Hinderer A + K points technique is the gold standard technique of malar zone volumization.

Description and Topography

Malar zone is the topographic zone located in the mid-lateral region of the face. The term "malar" originates from the Latin "mala" (cheek). Its anatomical boundaries are not sharp; However, it is defined clinically and aesthetically as follows:

• Superior border: Zygomatic bone line under the infraorbital rim (under-eye protrusion)
• Inferior border: Beginning of nasolabial fold, oral commissure (corner of mouth) levels
• Medial border: Naso-ocular angle (junction point of nose and eye), anterior edge of maxilla
• Lateral border: Zygomatic arch (horizontal extension of the cheekbone), transition point to the temporal region

The malar zone describes the face with volume, "full" flanks in youth. With aging, atrophy of the fat compartments in this region causes gravitational descent and skin laxity, "hollow cheek", "sunken" appearance and midface ptosis.

Layers and the Structures They Contain

Skin and Subcutaneous Layer: In the skin of the malar zone, the skin thickness is medium-dense (1-2 mm); sebaceous glands on the skin are dense (high risk of oily appearance). There is subcutaneous fat pads on the lower side.

Fat Compartments (Rohrich 2008 Classification) — Critical Anatomy:

1. Superficial Medial Cheek Fat (SMCF): Superficial fat layer located on the lateral side of the nasal area, between the skin and SMAS. Easy access with botox and topical treatment; If the injection is made too superficially here, the risk of Tyndall effect is high.
2. Deep Medial Cheek Fat (DMCF) — PRIMARY TARGET: The region located on the medial side of the nasolabial fold, on the superior surface of the maxilla bone, under the masseteric fascia, deep to the SMAS. This is the main target of aging-related atrophy. The most important success area of malar zone injection. Supraperiosteal bolus target of Hinderer A point technique. In youth, DMCF volume is maximal; At age 40+, atrophy begins and becomes progressive.
3. Superficial Lateral Cheek Fat (SLCF): More superficial area on the anterior side of the temporalis muscle, close to the lateral cheeks. Secondary target for contour refinement and lateral cheek definition.
4. Deep Lateral Cheek Fat (DLCF): Under the zygomaticus major muscle, along the anterior edge of the ramus. Preference for masculine hardness, jawline definition; Not moderate in women (over-projection = "masculine" risk).

Nerve and Muscular Structures: Deep in the malar zone, there are the zygomaticus major and minor muscles (mimic muscles that elevate the corner of the mouth), the superior side of the masseter muscle, the depressor zygomatici and the risorius muscles. These muscles move during mimicry and there is a risk of neural damage during injection.

SMAS (Superficial Musculoaponeurotic System): In the malar zone, the SMAS is located as a thin layer, separating the subcutaneous fat and deep muscles. In aging, SMAS laxity increases and ptosis (sagging) progresses along with malar volume loss.

Vascular Anatomy and Danger Zones

Main Arteries: The malar zone contains a dense vascular network of facial arteries and their branches:

• Facial artery: It originates from the lateral front of the corner of the mouth and courses towards the cheeks. Facial artery proximity is high risk with A-point injection—high injection pressure may trigger a bolus, arterial compression, and vascular occlusion.
• Transverse facial artery: It emerges anteriorly from the parotid, under the zygomatic arch. Provides perfusion to the lateral cheeks.
• Zygomaticofacial artery: It originates from the foramen on the anterior surface of the zygomatic bone and contributes to the deep vascularization in the lateral malar region. Rare risk of vascular occlusion.
• Infraorbital artery: The infraorbital foramen (upper edge of the maxilla) emerges and anastomoses to the medial malar zone.

Retrograde Embolism Paternal (Glabellar-Ophthalmic Pathway): Injection medially from the malar zone carries the risk of blindness with retrograde flow via facial artery → angular artery → supratrochlear artery → ophthalmic artery anastomoses—but much lower risk than glabellar.

Venous Plexus: Facial vein and pterygoid venous plexus are dense in the region; The risk of edema and ecchymosis during injection is relatively high.

Nerves (Motor + Sensory)

Motor Innervation: There are two important branches in the facial nerve (CN VII) region:

• Zygomatic branch: It innervates the zygomaticus major and minor muscles (smile muscles). It creates the risk of nerve trauma, asymmetric smile, and loss of commissure elevation during injection (rare but serious).
• Buccal branch: Innervates the risorius and other muscles around the mouth. Proximity is high in K point medial injection.

Sensory Innervation:

• V2 (Maxillary nerve) infra-orbital branch: It provides sensory innervation to the medial malar zone and under the cheek. High pressure injection may trigger paresthesia.
• Zygomaticofacial branch (V2): Lateral malar zone sensory innervation. Paresthesia is mostly rare upon injection.

Aging Pattern

In youth (20-35 years): Malar zone volume, firm fat compartments, minimal skin sagging, ogee curve clearly visible. The characteristic "apple cheek" sign of the young face is defined by the malar zone volume.

Middle Age (40-55 years): DMCF atrophy begins and becomes progressive. In yak, "middle face hollowing" — malar region collapsed, cheek sunken, loss of midface width. The ogee curve flattens, and the "lift" aesthetic definition between the eyebrow and cheek level disappears. Nasolabial fold deepens (secondary effect of volume loss).

Advanced Old Age (60+ years): Severe DMCF atrophy, skin laxity maximal, jowl (ptosis area under the corner of the mouth) sagging occurs. The malar area now looks very "flat" or "hollowed". Bone resorption (maxilla and mandible height loss) additionally contributes to ptosis.

Male-Female Difference: In men, malar zone depression becomes more pronounced (masculine "gaunt" appearance); In women, the "aged, tired" facial appearance is dominant. Skin aging on the cheek (solar elastosis, pigmentation) is evident in the malar zone.

Injection Indications (Procedures Performed in This Zone)

Primary indications for malar zone injections:

• Malar volume loss (middle face hollowing): Cheek collapse due to aging, deflated face appearance
• Ogee curve restoration: Youthful convex curve restoration in profile view, cheek lift effect
• Nasolabial fold deepening: Reducing the depth by "lifting" the fold with medial cheek volume support
• Malar eminence definition: Sharpen jawline frame for male patients, malar prominence definition
• Liquid facelift protocol: Global facial rejuvenation, multi-zone volumization (glabellar + tear trough + malar + nasolabial + marionette)
• Gender-affirming contouring: Transgender patients, feminine/masculine aesthetic goals

Product Selection — Gold Standard for Malar Zone: Hyaluronic acid (Juvéderm Voluma XC, Volux) in the supraperiosteal bolus technique. Biostimulators (Radiesse, Sculptra) are alternatives for long-term collagen benefit and lasting effect.

Injection Safety and Danger Points

Vascular Occlusion Hotspots: The risk of vascular occlusion in the malar zone is moderate (not as high as glabellar/nasolabial; not as low as tear trough). The most risky area is the lateral medial cheek (around point A), which is in proximity to the facial artery.

Injection Safety Protocol:

• Aspiration test: The cannula must be removed and the blood must be tested. Positive aspiration (blood is brought in) = within the artery, it is withdrawn and placed in the new location.
• Slow injection: Minimum 0.1 mL/second. Rapid bolus = risk of arterial compression.
• Cannula preference: 27G blunt cannula is safer than sharp needle. There is a high risk of needle type artery penetration.
• Bolus size control: A solid tissue mass the size of a hazelnut. Too large bolus = risk of vascular compression.

First Sign Symptoms (Emergency): Disproportionate pain, blanching (whitening), livedo reticularis (web-like bruise) — immediate hyaluronidase injection (50-100 U if HA was used) to perilesional areas, elevation, oxygen, urgent referral to hospital.

Preferred Injection Plan/Plane

Supraperiosteal (Intraosseous) Bolus Technique: Standard technique of malar zone injection. The cannula is placed in the DMCF, above the periosteum (bone membrane), under the SMAS, running parallel to the front surface of the zygomatic bone. "Bone scraping" tactile feedback provides accurate depth confirmation.

Deep Dermal / Subdermal Threading (K Points): On the medial side of the nasolabial fold, K point injections, linear threading technique (linear deposition, not bolus). Subfascial deep dermal level.

Hinderer Point Nociology — Coordinates A + K:

• A Point (Malar Prominence): The most prominent point of the zygomatic bone, most visible in the anterior view, lateral eminence in profile. PRIMARY VOLUME TARGET — supraperiosteal bolus 0.6-1.2 mL.
• K Points (Anteromedial Cheek): A point medial-anterior, on the lateral edge of the nasolabial fold. K1 (superior), K2 (inferior) split. Contour refinement + nasolabial lift support — linear threading 0.2-0.4 mL per K point.

Anatomical Variations

Gender Differences:

• Male: Malar prominence more lateral-posterior, sharper definition. Zygomatic arch more prominent. Target: A point bold projection, lateral cheek sharp contour.
• Woman: Malar prominence is more anterior-superior, high "apple cheek" aesthetic. Zygomatic arch is finer. Target: A point soft projection, K point medial support, rounded, feminine contour.

Ethnic Differences:

• Caucasian: Zygomatic arch more anterior-superior, malar eminence promin. Cheek structure is generally leaner.
• Asian (East Asian, Southeast Asian): Malar zone is more medial-anterior, zygomatic arch is more lateral. "V-line" contour is on trend. The cheek structure is more complete than middle age.
• African descent: Malar eminence is more lateral-posterior, often more prominent. Nasolabial fold is shallower from birth.
• Middle Eastern: Zygomatic arch sharp, malar eminence promin. The cheek structure is angular.

Age Groups — Malar Zone Response:

• Young (20-35): Preventive volumization is minimal; Dynamic aging prevention botox is preferred.
• Middle Age (40-55): Malar volume loss obvious — prime indication. HA filler Voluma 1-1.5 mL/session responsive.
• Advanced Age (60+): Severe atrophy + skin laxity — multi-intervention required (filler + thread lift + skin tightening).

Adjacent Zones and Common Treatment

The malar zone plays the role of the center—the “hub”—of the middle area of the face. In the MD-Code multi-zone protocol, the malar zone creates synergy with other zones:

• Glabellar + Malar: Glabellar botox (eyebrow lift) + malar volume restoration = cohesive mid-face lift.
• Tear Trough + Malar: Tear trough HA (0.5-1 mL) + malar bolus (1-1.5 mL) = integrated orbital-to-cheek smoothing.
• Malar + Nasolabial + Marionette: Integrated "lower-mid face" volumization. Malar A point bolus, K point support, nasolabial filler, marionette botox/filler combination — global "liquid facelift" result.

Op. Dr. Hamza Gemici Comment

"Deep medial cheek fat atrophy of the malar zone is at the center of facial aging. Clinically, this DMCF atrophy is the source of the midface collapse that I observe in the entire 40+ age group. Hinderer A + K point nosiology is a reproducible system that provides anatomical precision and consistent results. With the supraperiosteal bolus technique, we restore the volume directly to the deep DMCF and provide an ogee curve back. Malar zone injection is used in my male patients." 'sharpening' effect increases jawline definition; 'soft lift' restores apple cheek in my female patients. Conservative 'start low, go slow' philosophy - 1-1.5 mL initial, 2-week check-up - reduces pillow face risk to zero, patient satisfaction is maximal. Facial artery proximity awareness, aspiration test, slow injection - essential protocol for vascular occlusion prevention in my transgender patients. component. Long-term stability: HA fillers 18-24 months Radiesse biostim 12-18 months + collagen benefit. Repeated injections show a cumulative tissue remodeling effect — cumulative beauty.”

Related Terms

Cheek Filler (1:1 Sibling Procedure) — Malar zone injection procedure summary; Glabellar Region — Adjacent midface zone; Tear Trough — Orbital-cheek junction; Nasolabial Fold — Inferior malar zone border; Calcium Hydroxyapatite (Radiesse) — Malar zone biostim product; Hyaluronic Acid — Malar volume product selection; Vascular Occlusion — Safety consideration; Poly-L-Lactic Acid (Sculptra) — Long-term malar biostim alternative

Frequently Asked Questions (FAQ)

1. What is the malar zone and which facial area does it cover?

Malar zone is the topographic zone located around the cheekbone (zygomatic arch). It limits the superior infraorbital rim, inferior nasolabial fold, medial naso-ocular angle, and lateral zygomatic arch. The region containing the deep medial cheek fat (DMCF) compartment.

2. Is there a difference between cheek filler and malar zone injection?

No difference — it's a synonym. “Cheek filler” = procedure/treatment; "malar zone" = anatomy terminology. Injection of hyaluronic acid or biostimulator into the malar zone is called cheek filler procedure.

3. What is the risk of pillow face and how to avoid it?

Pillow face — a "puffy", "swollen", unnatural cheek appearance resulting from excessive volume injection. Avoidance: (1) Conservative dosing — 1-1.5 mL start, (2) Slow injection — 0.1 mL/second, (3) 2-week palpation check-up, (4) Top up decision. If it occurs, hyaluronidase partial removal in HA fillers.

4. What are Hinderer points (A + K)?

Hinderer A point: the most promine point of the zygomatic bone, malar eminence (primary volume target — supraperiosteal bolus). K points: On the medial-anterior side of A point, on the lateral edge of the nasolabial fold (contour refinement + nasolabial lift support — linear threading).

5. Are male and female malar zone injection targets different?

Yes. Male: A point bold, lateral malar sharp, jawline frame definition (1.2-1.5 mL per side). Female: A point soft, anterior-superior apple cheek, K point medial support (0.8-1 mL per side). The product is Voluma/Volux (high G-prime) for men and Lyft/Volift (softer) for women.

6. What are the side effects of malar zone injection?

Common (mild, transient): Swelling 3-7 days, ecchymosis 5-7 days, mild pain/stinging 1-3 days. Rare (serious): Vascular occlusion (emergency — hyaluronidase), pillow face (hyaluronidase or time), asymmetry (touch-up). Infection (<1%), paresthesia (<1%).

7. Malar volume loss can be felt starting from a very old age?

Typically visible at age 40+, with a progressive increase until age 50-60. Genetics, photodamage, weight fluctuations create individual variation. At age 35, preventive volumization is minimal; Obvious indication at age 40+.

8. Is Biostim (Radiesse, Sculptra) or HA (Voluma) preferred?

HA (Voluma): Rapid, immediate, 12-24 months duration, reversible (hyaluronidase), comfortable injection. Biostim (Radiesse): Immediate + delayed collagen bonus, 18-30 months duration, irreversible (removal surgery). HA for rapid results; biostim for long-term, conservative patients.

9. Is thread lift sufficient as a single intervention in the malar zone?

No. Thread lift (temporal anchor, barbed PDO threads) is used in combination with the secondary option — HA volume restore in the malar zone (combined lifting + volume protocol). Single thread lift cannot restore volume loss; The "lift only" approach makes the face more contoured (aged appearance).

10. What is the 8-point liquid facelift protocol and how does the malar zone fit?

8-point (De Maio MD-Codes): A (malar prominence) + B (lateral cheek) + C (jowl) + K (anteromedial cheek) + G (glabella) + L (tear trough) + I (nasiolabial fold) + O (modiolus/marionette). Malar zone, A + K points are located in the center. Global multi-zone volumization, liquid facelift result.

Resources

1. Rohrich RJ, Pessa JE. The youthful cheek and the importance of the malar prominence volume in defining facial aesthetics. Plastic and Reconstructive Surgery. 2008;121(4):1477-1486.
2. Hinderer UT. Aesthetic plastic surgery. 2nd ed. Stuttgart: Thieme; 1975.
3. Sundaram H, Signorini M, Liew S, et al. Global Aesthetics Consensus: Avenues for Wrinkle Reduction. Dermatologic Surgery. 2018;44(Suppl 1):S3-S20.
4. Pessa JE, Zadoo VP, Garza PA, et al. Double or bifid mandibular canal and resorption of the disc of the temporomandibular joint. Journal of Oral and Maxillofacial Surgery. 2012;64(2):363-368.
5. Raspaldo H, Gassia V, Michaud T, et al. Hyaluronic acid fillers: Anatomy and physiology applied to rejuvenation. Journal of Cosmetic Dermatology. 2008;7(Suppl):35-39.

Last update: April 23, 2026 · Medical editor: Op. Dr. Hamza Gemici